Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Eli Lilly Japan and Mitsubishi Tanabe Pharma Introduced Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®
Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation has introduced “Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®”....
Regenxbio Discovered Novel RGX-202 for the Tretament of Duchenne Muscular Dystrophy
Regenxbio discovered novel RGX-202, a one-time gene therapy candidate for the treatment of Duchenne muscular dystrophy. RGX-202 is designed to deliver a novel microdystrophin transgene containing functional elements of the C-terminal (CT) domain found in naturally occurring dystrophin....
Janssen Pharmaceutical Discovered First-of-its-Kind ERLEADA® (apalutamide)
The Janssen Pharmaceutical Companies of Johnson & Johnson discovered first-of-its-kind ERLEADA® (apalutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC)....
Moderna and Merck Developed Novel mRNA-4157/V940, Personalised mRNA Cancer Vaccine
Moderna and Merck developed mRNA-4157/V940, an investigational personalised mRNA cancer vaccine in combination with KEYTRUDA® (pembrolizumab) for the treatment of high-risk melanoma following complete resection. The combination of mRNA-4157/V940 with KEYTRUDA demonstrated efficacy...
First-of-its-Kind SYFOVRE™ (pegcetacoplan injection) Developed for Geographic Atrophy (GA)
Apellis Pharmaceuticals developed SYFOVRE™ (pegcetacoplan injection) for the treatment of secondary age-related macular degeneration (AMD). SYFOVRE™ (pegcetacoplan injection) is the only therapy approved for geographic atrophy (GA). By targeting C3, pegcetacoplan is designed to provide comprehensive control...
Abbisko Therapeutics Discovered Novel CSF-1R Inhibitor Pimicotinib (ABSK021)
Abbisko Therapeutics discovered novel CSF-1R inhibitor Pimicotinib（ABSK021) for the treatment of tenosynovial giant cell tumour (TGCT) patients not responding to surgery. Pimicotinib is the first new generation CSF-1R drug candidate in the world. It is a novel, oral, highly selective and highly potent small molecule inhibitor of CSF-1R. Several studies have shown...
Loxo@Lilly Discovered Novel Jaypirca™ (pirtobrutinib) for Adult Patients
Loxo@Lilly the oncology unit of Eli Lilly and Company discovered novel Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Jaypirca is the first and only BTK inhibitor specifically discovered for patients with mantle cell lymphoma...
Novel IBI351 (KRASG12C Inhibitor) Discovered for the Treatment of Advanced Non-Small Cell Lung Cancer
Innovent Biologics, Inc. Discovered novel IBI351/GFH925(KRASG12C Inhibitor) as monotherapy for the patients previously treated with advanced non-small cell lung cancer. It is applicable for patients with KRASG12C mutation who have received at least one prior line of systemic therapy....
Efruxifermin, Novel Therapy Discovered for Nonalcoholic Steatohepatitis (NASH)
Akero Therapeutics, discovered novel Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH). Efruxifermin (EFX) also known to be AKR-001, currently being evaluated in the ongoing Phase 2b HARMONY study is the main leading candidate for NASH...
Novel Avacincaptad Pegol Developed for Geographic Atrophy
IVERIC bio, Inc developed avacincaptad pegol to treat geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitorhave shown positive results from the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal...
